Related Experiment Videos
Drug development in prostate cancer
1Department of Medicine, University of Wisconsin Comprehensive Cancer Center, Madison, USA.
Abstract:
Despite strategies aimed at early detection and treatment, prostate cancer remains a leading cause of morbidity and mortality among males. Current therapies have limited impact on the natural history of metastatic hormone-refractory prostate cancer (HRPC). With an improved understanding of tumor biology, including apoptosis, differentiation, cell cycling and signaling, and angiogenesis, many potential new targets for therapy have been unveiled. Modulation of these processes may result in cytotoxic or cytostatic effects. The evaluation of therapies based on manipulation of these targets may not be adequately addressed by current study designs and traditional parameters of efficacy. Examples of agents currently in clinical trials that illustrate some of the challenges presented to clinical investigators include monoterpenes such as perillyl alcohol (POH), vitamin D analogs, flavones such as flavopiridol, and angiogenesis inhibitors. Agents such as these are aimed at unique cellular targets and will require novel approaches to determine their clinical utility. Unfortunately, in the United States, only a small proportion of cancer patients, including prostate cancer patients, are enrolled in clinical trials. We must do better to efficiently assess promising new treatment approaches and improve outcome for our patients.
Insights
New prostate cancer therapies targeting tumor biology show promise but require novel clinical trial designs. Improving patient enrollment in trials is crucial for assessing these innovative treatments and enhancing outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Clinical Trials
Background:
- Prostate cancer is a significant cause of male morbidity and mortality.
- Metastatic hormone-refractory prostate cancer (HRPC) has limited treatment options.
- Advances in understanding tumor biology reveal new therapeutic targets.
Purpose of the Study:
- To highlight challenges in evaluating novel prostate cancer therapies.
- To emphasize the need for innovative clinical trial designs.
- To advocate for increased patient participation in clinical trials.
Main Methods:
- Discussion of emerging therapeutic targets (apoptosis, angiogenesis, etc.).
- Examples of agents in clinical trials (perillyl alcohol, vitamin D analogs, flavopiridol, angiogenesis inhibitors).
- Analysis of limitations in current study designs and efficacy parameters.
Main Results:
- Novel agents target specific cellular pathways, requiring new evaluation methods.
- Current trial designs may not adequately assess the efficacy of these targeted therapies.
- Low patient enrollment in clinical trials hinders progress.
Conclusions:
- Novel approaches are needed to determine the clinical utility of new prostate cancer therapies.
- Enhanced clinical trial designs and increased patient enrollment are essential.
- Improving the assessment of promising treatments can lead to better patient outcomes.